RE:RE:Background to Gilead's $21 Bln acquisition of Immunomedics
Dec. 10, 2021 - Gilead'sTrodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Gilead's interests in TNBC match those of Roche and Merck USA's and therefore ONCY's work in TNBC particularly match those of the aforementioned companies since pelareorep can be combined their respective therapeutic agents,.
https://www.biospace.com/article/releases/trodelvy-demonstrates-clinical-benefit-for-black-patients-consistent-with-full-metastatic-triple-negative-breast-cancer-population-in-ascent-study/